Maraviroc as an Immunomodulatory Drug for Antiretroviral-Treated HIV Infected Patients Exhibiting Immunologic Failure.

Trial Profile

Maraviroc as an Immunomodulatory Drug for Antiretroviral-Treated HIV Infected Patients Exhibiting Immunologic Failure.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2013

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jul 2012 Actual initiation date changed from Aug 2008 to Sep 2008 as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Actual end date Jul 2010 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top